Please select an indication to learn more about LENVIMA® (lenvatinib)
LENVIMA is indicated in combination with everolimus for the treatment of patients with advanced renal cell carcinoma (RCC) following one prior anti‑angiogenic therapy.
The health information contained herein is provided for educational purposes only and is not intended to replace discussions with a health care provider.
All decisions regarding patient care must be made with a health care professional, considering the unique characteristics of the patient.
This site is intended for U.S. health care providers only. The product discussed herein may have different product labeling in different countries.
To report suspected adverse reactions, contact Eisai Inc. at 1-888-274-2378 or the FDA at 1-800-FDA-1088 or www.FDA.gov/medwatch.
© 2017 Eisai Inc. All rights reserved. LENV-US0264(2) us.eisai.com